Featured Publications
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli M, Roy S, Newell R, Pestano L, Dickinson B, Rigby K, Herazo-Maya J, Jenkins G, Ian S, Saini G, Johnson SR, Braybrooke R, Yu G, Sauler M, Ahangari F, Ding S, DeIuliis J, Aurelien N, Montgomery RL, Kaminski N. A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. EBioMedicine 2022, 85: 104304. PMID: 36265417, PMCID: PMC9587275, DOI: 10.1016/j.ebiom.2022.104304.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisNon-human primatesPulmonary fibrosisAnimal modelsPro-fibrotic genesAnti-fibrotic efficacyMiR-29 mimicsHuman peripheral bloodMiR-29b levelsHuman lung fibroblastsIPF patientsIPF diagnosisPeripheral bloodReduced fibrosisAdverse findingsPotential therapyLung slicesTGF-β1Relevant dosesLung fibroblastsNIH-NHLBIFibrosisTherapyCollagen productionProfibrotic gene program
2022
Leveraging Cell-Specific Disease Signatures to Predict New Drug Therapies for Idiopathic Pulmonary Fibrosis
Adams T, Song Q, Justet A, Mcdonough J, DeIuliis G, Yan X, Bar-Joseph Z, Kaminski N. Leveraging Cell-Specific Disease Signatures to Predict New Drug Therapies for Idiopathic Pulmonary Fibrosis. 2022, a2318-a2318. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2318.Peer-Reviewed Original Research
2016
Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies
Tan J, Tedrow JR, Dutta JA, Juan-Guardela B, Nouraie M, Chu Y, Trejo Bittar H, Ramani K, Biswas PS, Veraldi KL, Kaminski N, Zhang Y, Kass DJ. Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies. American Journal Of Respiratory And Critical Care Medicine 2016, 194: 1392-1402. PMID: 27310652, PMCID: PMC5148141, DOI: 10.1164/rccm.201509-1865oc.Peer-Reviewed Original ResearchConceptsRelaxin/insulin-like family peptide receptor 1Idiopathic pulmonary fibrosisIPF lung fibroblastsRXFP1 expressionLung fibroblastsPulmonary fibrosisFamily peptide receptor 1RXFP1 gene expressionLung Tissue Research ConsortiumPulmonary functionIPF lungsBleomycin injuryPotential therapyCollagen depositionFibrotic diseasesPatientsDemographic dataPotential efficacyReceptor 1Donor controlsTherapyRelaxin-like peptideGrowth factorGene expressionFibrosis
2014
Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report
Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O’Riordan T, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 214-222. PMID: 24160862, PMCID: PMC3983890, DOI: 10.1164/rccm.201306-1141ws.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIdiopathic pulmonary fibrosisAlveolar epithelial injuryEffective medical therapyRole of inflammationTime of diagnosisPatient advocacy groupsMedian survivalMedical therapyEpithelial injuryPulmonary fibrosisPulmonary fibrosis researchIPF therapyIPF researchPreclinical modelingDrug AdministrationPatient communityU.S. FoodNHLBITranslation of discoveriesClinical researchersPatientsFibrosis researchTherapyDiseaseAberrant repair
2012
Personalized medicine: applying omics to lung fibrosis
Herazo-Maya JD, Kaminski N. Personalized medicine: applying omics to lung fibrosis. Biomarkers In Medicine 2012, 6: 529-540. PMID: 22917154, PMCID: PMC3517740, DOI: 10.2217/bmm.12.38.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisFibrotic lung diseaseLung transplantPulmonary fibrosisLung fibrosisLung diseaseUnknown etiologyChronic diseasesSporadic formsHigh mortalityPatient careTreatment of diseasesDrug studiesCost-effective strategyDiseaseFibrosisDiagnosisPersonalized medicinePatientsTransplantEtiologyTherapyMortalityCarePrevention
2005
Can Blood Gene Expression Predict Which Patients with Multiple Sclerosis Will Respond to Interferon?
Kaminski N, Achiron A. Can Blood Gene Expression Predict Which Patients with Multiple Sclerosis Will Respond to Interferon? PLOS Medicine 2005, 2: e33. PMID: 15736992, PMCID: PMC549584, DOI: 10.1371/journal.pmed.0020033.Peer-Reviewed Original Research
2002
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature Medicine 2002, 8: 500-508. PMID: 11984595, DOI: 10.1038/nm0502-500.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsAutopsyChronic DiseaseEncephalomyelitis, Autoimmune, ExperimentalFemaleGranulocyte Colony-Stimulating FactorHumansInflammationInterferon-gammaInterleukin-17Interleukin-6MiceMice, Inbred C57BLMultiple SclerosisOligonucleotide Array Sequence AnalysisReceptors, FcReproducibility of ResultsTranscription, GeneticConceptsExperimental autoimmune encephalomyelitisMultiple sclerosis lesionsMS lesionsAutoimmune encephalomyelitisSclerosis lesionsGranulocyte colony-stimulating factorCommon γ chainColony-stimulating factorGene microarray analysisAcute phaseInflammatory cytokinesInterleukin-6Chronic diseasesLesionsNew targetsEncephalomyelitisTherapyDownstream pathwaysMicroarray analysisΓ-chainMicroarray studiesInflammationChronicCytokinesInterferon